A new meta-analysis by Ettehad and colleagues, which included >613,000 patients with hypertension from randomized, controlled trials, clearly demonstrates that antihypertensive medication reduces cardiovascular events and death in all patients, including those with systolic blood pressure <130 mmHg and regardless of concomitant diseases. The risks of stroke and heart failure were particularly reduced.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ettehad, D. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet http://dx.doi.org/10.1016/S0140-6736(15)01225-8 (2015).
SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).
ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
Perkovic, V. & Rodgers, A. Redefining blood-pressure targets — SPRINT starts the marathon. N. Engl. J. Med. 373, 2175–2178 (2015).
Kario, K. Essential Manual of 24 Hour Blood Pressure Management From Morning to Nocturnal Hypertension (Wiley–Blackwell, 2015).
Collins, F. S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793–795 (2015).
Kario, K. et al. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension 64, 989–996 (2014).
Webb, A. J., Fischer, U., Mehta, Z. & Rothwell, P. M. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 375, 906–915 (2010).
McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 (2014).
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kario, K. Benefits of strict blood-pressure lowering in hypertension. Nat Rev Cardiol 13, 125–126 (2016). https://doi.org/10.1038/nrcardio.2016.13
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2016.13
This article is cited by
-
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond
Current Cardiology Reports (2018)
-
Perfect 24-h management of hypertension: clinical relevance and perspectives
Journal of Human Hypertension (2017)